An era of pharmacoeconomics and outcomes research is dawning Newsletter Article 17 February 2013 Pages: 2 - 2
An independent centre for pharmacoeconomics in the UK? Tom Walley Newsletter Article 17 February 2013 Pages: 3 - 3
Use cost-analysis tools to assess managed-care programmes Newsletter Article 17 February 2013 Pages: 4 - 4
Lower concentration of sporicidal effective and cost saving Newsletter Article 17 February 2013 Pages: 5 - 5
Omeprazole offers clinical and economic advantages over ranitidine Newsletter Article 17 February 2013 Pages: 7 - 7
Ribavirin treatment guidelines curb healthcare costs Newsletter Article 17 February 2013 Pages: 8 - 9
Cost-saving predictors of response to breast cancer therapy Newsletter Article 17 February 2013 Pages: 9 - 9
Long-term citalopram more effective, less costly than standard therapy? Newsletter Article 17 February 2013 Pages: 11 - 11
Ceftriaxone favoured over cefixime, aztreonam for septicaemia Newsletter Article 17 February 2013 Pages: 12 - 13
Strontium 89 - palliating bone cancer pain and cost saving Newsletter Article 17 February 2013 Pages: 13 - 13
Should zidovudine be used to prevent vertical HIV transmission? Newsletter Article 17 February 2013 Pages: 14 - 14
QOL diaries useful, questionnaires more comprehensive Newsletter Article 17 February 2013 Pages: 14 - 14
Patients may pay the price of cost containment in Italy Newsletter Article 17 February 2013 Pages: 15 - 15
Medicare urged to consider inappropriate drug use in elderly Newsletter Article 17 February 2013 Pages: 16 - 16